Cargando…
p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
Malignant mesothelioma (MM) generally occurs as a pleural tumour, related to the inhalation of asbestos fibres. It is highly aggressive and largely unresponsive to treatment. The incidence of MM is particularly high in Western Australia because of the extensive blue asbestos mining operations that o...
Autores principales: | Creaney, J, McLaren, B M, Stevenson, S, Musk, A W, Klerk, N de, Robinson, B W S, Lake, R A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363614/ https://www.ncbi.nlm.nih.gov/pubmed/11139313 http://dx.doi.org/10.1054/bjoc.2000.1529 |
Ejemplares similares
-
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014) -
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019) -
Discovery of new biomarkers for malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2015) -
Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
por: Meniawy, T M, et al.
Publicado: (2013) -
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)